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The neuromuscular junction (NMJ) forms the synaptic connection between a motor neuron 
and a skeletal muscle fibre. In order to achieve a sustained muscle contraction, this synapse 
has to reliably transmit motor neuronal action potentials onto the muscle fibre. To guarantee 
successful transmission even during intense activation of the NMJ, a safety factor of 
neuromuscular transmission exists. In the neuromuscular disorder myasthenia gravis (MG), 
autoantibodies are directed against acetylcholine receptors or, in the rarer variants, to other 
postsynaptic NMJ proteins. This causes loss of functional acetylcholine receptors, which 
compromises the safety factor of neuromuscular transmission, leading to the typical fatigable 
muscle weakness of MG. With intracellular micro-electrode measurement of (miniature) 
endplate potentials at NMJs in ex vivo nerve-muscle preparations from MG animal models 
these functional synaptic defects have been determined in much detail. This review will 
describe the electrophysiological events at the normal NMJ and the patho-electrophysiology 




Detailed electrophysiological investigation of synaptic signals at the neuromuscular junction 
(NMJ) has been instrumental to elucidate many basic aspects of synaptic transmission and to 
understand the pathophysiological mechanisms underlying neuromuscular synapthopathies. 
In this review we will describe the electrophysiology of the NMJ and the patho-
electrophysiology of NMJs of animal models for the autoimmune neuromuscular disorder 
myasthenia gravis (MG). 
 
Electrophysiological signals at the neuromuscular junction 
Intracellular microelectrode recordings of synaptic electrophysiological signals at the NMJ 
can be made in muscle fibres of unfixed muscle specimens dissected from MG patients or 
experimental animals. For a more methodological description of such an electrophysiological 
analysis at the NMJ, the reader is referred to Ref. 1.1 
The principal task of the NMJ is to transfer motor neuronal action potentials onto the 
skeletal muscle fibre in an exactly one-to-one fashion, irrespective of the neuronal firing 
frequency and duration. Only then, a properly sustained, tetanic muscle contraction can be 
guaranteed. Although this synaptic task of the NMJ seems a rather simple one, many highly 
complex structural and functional subcellular and molecular specializations are underlying. 
To understand the synaptic defects at the NMJ in the condition of MG it is essential to know 
its normal function, which we will briefly describe first. 
The unitary signals of electrically excitable cells such as neurons and muscle cells are the 
action potentials. These all-or-none depolarizations are enabled by the existence of a resting 
membrane potential and the presence of several types of ion channels in the cell membrane. 
Action potentials are actively conducted over the membrane of excitable cells. Their rising 
phase is caused by Na+ influx through voltage-gated NaV channels. In the nodes of Ranvier of 
motor axons these are of the NaV1.6 type while in skeletal muscle fibres these are of the 
NaV1.4 type.
2,3 The motor neuronal action potential travels towards the nerve terminal in a 
jumpwise fashion via the axonal nodes of Ranvier, where the NaV channels are present at 
high density and absence of myelin allows for Na+ membrane flux. The decaying phase of 
action potentials is due to NaV inactivation and opening of rectifying voltage-gated potassium 
channels. The small dimensions of mammalian motor axons (i.e. a diameter of only a few 
microns) preclude direct voltage measurements. In fact, much of what we know about ion 
fluxes and ion channel behaviour underlying axonal action potential generation and 
conduction has come from pioneering studies on the ~1 mm diametered giant motor axons of 
the squid.4 When the neuronal action potential reaches the motor nerve terminal, it triggers 
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opening of voltage-gated Ca2+ channels which are of the CaV2.1 type (Fig. 1).
5 These 
channels are present at so-called active zones, which are presynaptic molecular complexes 
where structural proteins keep functional proteins in optimal position to control 
neurotransmitter release.6 CaV2.1 channels are anchored at active zones by binding to 
structural presynaptic and synaptic cleft molecules such as bassoon, CAST/erc2 and laminin-
β2, either to the pore-forming subunit or to accessory subunits.7,8 About 2.5 active zones are 
present in every μm2 of presynaptic membrane, implying the presence of ~800 active zones 
per nerve terminal, at least in the mouse.9 Action potential-induced opening of the 
presynaptic CaV2.1 channels results in Ca
2+ influx into the motor nerve terminal along its 
steep concentration gradient (i.e. extracellular ~2 mM, intracellular ~200 nM). The ensuing 
increase of cytoplasmatic Ca2+ concentration in the vicinity of the active zone activates a 
complex of molecules which orchestrate exocytosis of synaptic vesicles that are filled with 
the neurotransmitter ACh. The principal components of this complex are the Ca2+ sensor 
synaptotagmin and the SNARE proteins synaptobrevin, SNAP-25 and syntaxin. 
Synaptotagmin and synaptobrevin are present in the membrane of the synaptic ACh vesicles, 
while SNAP-25 and syntaxin are embedded in the presynaptic membrane. Together (and 
modulated by many factors), these proteins govern the docking and controlled exocytosis of 
transmitter containing vesicles, leading to neurotransmitter release into the synaptic space.10 
Each ACh vesicle contains a 'quantum' of ~10,000 ACh molecules. Per nerve impulse, a 
number of these quanta (the 'quantal content') is released simultaneous. The quantal content is 
dependent on many factors, such as age, species, muscle type etc. Human nerve terminals, 
which are small (~100 µm2), have a quantal content of ~20, while the larger mouse nerve 
terminals (~250 µm2) release ~50 ACh quanta per nerve impulse.11,12 Roughly, the quantal 
content is determined by the absolute number of active zones present in a motor nerve 
terminal, as each active zone has a more or less fixed chance of ~10% of releasing an ACh 
quantum upon CaV2.1 channel activation by an action potential.
9,13 In addition to the action 
potential-evoked simultaneous exocytosis of multiple ACh quanta, now and then (roughly 
once per second at the mouse NMJ) there is exocytosis of a single ACh quantum. This is a 
spontaneous process which can presumably be regarded as a spillage of quanta from the very 
large pool of ACh vesicles. Electrophysiological experiments using the specific CaV2.1 
blocker -Agatoxin-IVA showed that the rate of spontaneous uniquantal ACh release is for 




Once quanta are exocytosed, ACh molecules diffuse into the ~50 nm wide synaptic cleft 
were a large proportion of the neurotransmitter is degraded by basal lamina-anchored 
acetylcholinesterase (AChE), limiting the lateral spread of ACh away from the releasing 
active zone. Remaining ACh can then bind to the muscle ACh receptors (AChRs), localized 
at high density (~10,000/µm2) on the tops of the typical postsynaptic folds (Fig. 1.). Skeletal 
muscle fibres express nicotinic AChRs.15-17 These are ligand-gated ion channels that consist 
of five transmembrane subunits (i.e. two α1, a β1, a δ and an ε subunit) in the adult situation. 
Embryonic NMJ AChRs or AChRs that appear on the extrasynaptic muscle fibre surface after 
denervation have a  subunit instead of the ε subunit. The binding of an ACh molecule to 
each of the binding pockets formed by the two α1 subunits with one of their neighbouring 
subunits causes conformational changes which result in opening of the ion pore.15 AChRs 
have a single channel conductance of ~60 pS and their opening at physiological condition 
results in influx of mainly Na+ ions, as well as some efflux of K+. A few percent of the net 
inward ion current through the muscle AChR is carried by Ca2+ ions.18 Together, the multiple 
ACh quanta released by a neuronal action potential open thousands of AChRs and the 
resulting net influx of positive charge causes a local depolarization of the postsynaptic 
membrane. This is the endplate potential (EPP), which has a duration of a few ms and is 
terminated when ACh becomes degraded by AChE. The amplitude of an EPP varies between 
species, muscle type, age etc., and lies mostly between 15 and 30 mV. The purpose of the 
EPP is to cause opening of many voltage-gated NaV1.4 channels, which reside in the bottom 
of the postsynaptic folds. This results in the upstroke of an action potential, which will travel 
away from the NMJ in two directions and will subsequently trigger T-tubular mechanisms 
that elicit muscle fibre contraction. While the EPPs are directly functional, the spontaneous 
release of single ACh quanta leads to a miniature EPPs (MEPPs) of ~0.3-1.5 mV (Fig. 2), 
which are too small to trigger a muscle fibre action potential. In the electrophysiological 
analysis of the MG NMJ, the MEPP amplitude can be used as an indicator for the density of 
functional AChRs (see below). In addition, their uniquantal amplitude is used in quantal 
content calculations. To this end, the amplitude of the multiple quanta-based EPP is divided 
by that of the mean uniquantal MEPP, measured at the same NMJ.1  
Muscle fibres have a depolarization threshold for action potential firing which is 
depending on the density and electrophysiological characteristics of NaV1.4 channels. Two 
factors assure successful synaptic transmission at the NMJ: 1) a high NaV1.4 density at the 
NMJ causes a local lowering of the firing threshold, facilitating muscle fibre action potential 
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induction by EPPs19-23; 2) in spite of this relatively low firing threshold, EPPs are generally 
much larger than the minimal amplitude to reach the threshold.12,24 This safety factor in 
neuromuscular transmission amounts ~2-3 (at rodent NMJs, at human NMJs it is ~2).25 While 
such a safety factor might seem superfluous this is not the case. It protects the NMJ against 
transmission failure when quantal content (and thus also the EPP) runs down during intense 
synaptic activity (Fig. 2B). The underlying reason is that some neuro-exocytotic factors 
become limiting. EPP rundown can be ~20-30% during trains of physiological activity of the 
NMJ, which can be at rates of 20-100 Hz.26 The rundown of EPPs at human NMJs is 
somewhat more prominent than in rodent NMJs, by ~40%.27 Only by having a considerable 
safety factor can the neuromuscular transmission at the NMJ exactly follow the motor 
neuronal firing pattern. In this way sustained tetanic contraction is warranted (Fig. 2C).  
 
Aberrant electrophysiology at the neuromuscular junction in myasthenia gravis 
The electrophysiological problem at the NMJ in MG is that the EPPs are smaller than in 
normal NMJs. During prolonged synaptic activity they can even become of subthreshold 
amplitude so that they can no longer trigger muscle fibre action potentials (Fig. 2B). Thus, 
there is a substantial reduction of the safety factor of neuromuscular transmission at MG 
NMJs. Due to slight variability of EPP amplitude during prolonged activity, a myasthenic 
NMJ in a critical state with peri-threshold EPPs will have intermittent transmission failures. 
This phase will progress into a more permanent synaptic failure state after some time of 
activity due to ongoing EPP rundown. If many NMJs in the skeletal muscles of MG patients 
are in such a state of having progressive block of NMJ transmission, this leads to the typical 
symptoms of fatigable muscle weakness. If EPPs are too small already from the start of NMJ 
activity to reach the firing threshold, the connected muscle fibre will not contract at all. This 
will contribute to a degree of permanent muscle weakness.  
How do the EPPs at MG NMJs become reduced in amplitude? The answer is loss of 
postsynaptic sensitivity for the neurotransmitter ACh due to reduced density of functional 
AChRs. The great majority (~85%) of MG patients has auto-antibodies (IgG1 and IgG3 type) 
which are directed against postsynaptic AChRs at NMJs. The effect of these autoantibodies is 
three-fold: 1) removal of AChRs due to cross-linking and subsequent internalization; 2) 
functional AChR block and 3) the activation of complement with formation of membrane-
attack complex that causes focal lysis.28,29 Together this results in the two main 
electrophysiological deficits which both contribute to reduction of the safety factor of 
neuromuscular transmission: 1) the EPPs become small due to the loss of a proportion of the 
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functional AChRs and 2) the firing threshold becomes elevated due to reduction of Nav1,4 
channel density due to the complement-mediated focal membrane damage at the postsynaptic 
NMJ (Fig. 2). 
 
AChR myasthenia gravis animal model electrophysiology 
The knowledge of these patho-electrophysiological mechanisms and the underlying 
autoimmunity at the NMJ in MG has come in large part from animal model studies. The first 
animal model for MG dates from 1973 when active immunization of rabbits was performed.30 
The animals were injected with a purified AChR fraction derived from electric organs of 
Electrophorus electricus, an eel species. After about one month, the rabbits developed flaccid 
muscle weakness. Similar to MG patients, the symptoms of muscle weakness improved when 
the animals were treated with neostigmine, an acetylcholinesterase inhibitor that increases the 
available ACh at the NMJ. Anti-eel AChR antibodies were detected in the rabbit serum. No 
ex vivo detailed electrophysiological measurements were performed at NMJs of these rabbits. 
Instead, electromyography during 40 Hz repetitive nerve stimulation was performed and 
showed a decrement of the compound muscle action potential that more or less stabilized at 
~40% after the fourth nerve stimulus. This is indicative of progressive NMJ transmission 
block, as also observed in MG patients in diagnostic clinical electromyographical testing. The 
decrement was corrected by neostigmine injection, further demonstrating NMJ dysfunction as 
the underlying culprit.  
In the same era, additional studies (re-)produced active immunization MG models in 
guinea pigs, rabbits, rats and rhesus monkeys, using eel AChR but also AChR derived from 
the ray Torpedo californica or marmorata.31-33 The models were termed 'experimental 
autoimmune MG' (EAMG). They showed fatigable muscle weakness and decrement of the 
compound muscle action potential, which could be normalized by acetylcholinesterase 
inhibitors. Another line of direct evidence for failure of NMJ transmission due to AChR 
block as cause in MG were rat studies in which α-toxin from the Formosan cobra, a known 
AChR blocker, was injected. This caused MG-like decrement of compound muscle action 
potentials which could be normalized by an acetylcholinesterase inhibitor.34 Another crucial 
finding, providing proof of the pathogenicity of MG autoantibodies, was that passive transfer 
to mice of purified IgG from MG patients induced pathophysiological effects at the NMJ.35 
This was the first study to show with ex vivo electrophysiological analyses using an 
intracellular micro-electrode that MEPPs at MG mouse NMJs had small amplitudes (~30% of 
normal), indicating lowered AChR density. Similarly, the first microelectrode studies of 
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NMJs in active immunization EAMG rats also clearly revealed small MEPPs.36,37 
Collectively, these early studies provided the first proof that the pathophysiological 
mechanism in MG is a decrease in AChR density due to auto-antibody attack at the NMJ and 
that a reduced MEPP amplitude forms the electrophysiological hallmark. Further passive 
transfer studies in which mice, rats and guinea pigs were injected with rat AChR monoclonal 
antibodies, were in line with these earlier studies as they confirmed MEPP reductions.38,39  
The second electrophysiological factor which contributes to safety factor reduction in MG 
is the elevation of the muscle fibre firing threshold. This is due to the complement-mediated 
postsynaptic membrane damage. It results not only in AChR density reduction, but also in 
removal of postsynaptic NaV1.4 channels from the bottom of the postsynaptic membrane 
folds, where they are enriched.21 In NMJs of a rat passive transfer MG model and in human 
MG biopsy NMJs it was shown that AChR antibodies indirectly cause reduced Nav1.4 
density via complement activation and thereby elevate the firing threshold at the NMJ by ~10 
mV.22,40 The AChR antibodies do not directly alter the electrophysiological features of the 
remaining NaV1.4 channels.
40 
In our own laboratory we developed non-immunological rat and mouse models for AChR 
MG by chronic injection of low doses of α-bungarotoxin, a near-irreversible blocker of 
AChRs.41,42 With careful dosing this produces controllable mild muscle weakness. The NMJ 
electrophysiology could be studied in much detail, also because in the 1990s the 
pharmacological tools µ-conotoxin-GIIIA and -B became available which can be used to 
selectively block NaV1.4 channels of the muscle fibre and thus prevent muscle fibre action 
potentials. In this way, EPPs can be measured without being disturbed by action potentials 
and the contraction these cause.43 From micro-electrode studies in the α-bungarotoxin-
induced rat MG model it appeared that the myasthenic NMJ tries to compensate the loss of 
AChR density by increasing the presynaptic ACh release per nerve impulse.43,44 This 
homeostatic increase of quantal content was confirmed in human AChR MG NMJs.11 The 
quantal content level of individual NMJs is inversely related to their myasthenic severity (i.e. 
as indicated by the reduction in MEPP amplitude). Therefore, local retrograde signalling is 
likely taking place. Multiple candidates for post- and presynaptic factors and the retrograde 
signals involved have been hypothesized, but the exact mechanism causing the compensatory 
increase of ACh release is not elucidated yet.44 An increased size of the presynaptic pool of 
ACh vesicles available for release might be of importance.45 The observed compensatory 
homeostatic reaction of the motor nerve terminal to the postsynaptic loss of functional AChR 
density might offer protection against synaptic failure of the myasthenic NMJs, especially in 
9 
 
mild myasthenic conditions. On the other hand, the increased quantal content is associated by 
a more intense rundown during high rate activity.11,43 This is possibly due to neuro-exocytotic 
factors becoming limiting sooner due to the higher demand. Thus, extra EPP rundown at MG 
NMJs might partly counterpoise a beneficial effect of increased quantal content. 
 
MuSK- and LRP4 myasthenia gravis animal model electrophysiology 
More recent MG animal modelling studies have focussed on the rarer variants of MG, with 
autoantibodies against the postsynaptic NMJ proteins muscle-specific kinase (MuSK) and  
low-density lipoprotein receptor-related protein 4 (LRP4). MuSK MG and LRP4 MG have 
some clinical and pharmacological features distinct from AChR MG, including the regional 
distribution pattern of the muscle weakness. For more detailed information the reader is 
referred to Ref. 28.28 MuSK and LRP4 are transmembrane proteins which are involved in the 
neuronal agrin-dependent embryonic formation of AChR clusters and their maintenance in 
later phases.46,47 The recently generated active- and passive immunization mouse models for 
MuSK and LRP4 MG have been very well-characterized with detailed ex vivo 
electrophysiological investigations (Table 1).48-55 Many electrophysiological similarities exist 
with the active- and passive immunization and toxin-induced models for AChR MG. In 
particular, the MEPPs are reduced in amplitude and frequency, and the EPPs are reduced in 
amplitude and have extra rundown during high-rate synaptic activity. A decrement of muscle 
action potentials has been found in electromyographical investigations of weak animals. 
Morphologically, there is clear fragmentation, dispersal and density reduction of AChR 
clusters in both the MuSK and LRP4 MG model NMJs. The only (but very distinct and 
important) difference from AChR MG in the electrophysiological analyses is that MuSK- and 
LRP4 MG model NMJs do not show increased quantal content. Rather, some studies have 
even shown a somewhat decreased quantal content, as compared to normal control NMJs. In 
more detailed NMJ analyses of MuSK MG mouse model electrophysiology it has also been 
shown that no inverse relationship exists between MEPP amplitude and quantal content at 
individual NMJs, indicating the absence of a synaptic homeostatic response to the reduced 
postsynaptic neurotransmitter sensitivity.55,56, JJ Plomp, unpublished data Similarly, absence of a 
compensatory increase in quantal content was shown in the few electrophysiological NMJ 
studies in human MuSK MG muscle biopsies published so far.27,57 Collectively, these studies 
suggest that MuSK and/or LRP4 are in some way involved in the mechanism underlying 
synaptic homeostasis at the myasthenic NMJ, possibly as postsynaptic sensing (co-)factor or 
as a source of retrogradely acting signalling molecules, e.g. by shedding of extracellular 
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fragments.58,59 Further electrophysiological and other types of studies will be needed to 
elucidate their exact roles.  
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normal AChR MG MuSK MG LRP4 MG 
CMAP decrement no yes yes yes 
MEPP amplitude ~1 mV reduced reduced reduced 
MEPP frequency ~1 /s same or reduced reduced reduced 
single EPP amplitude ~30 mV reduced reduced reduced 
high-rate EPP rundown ~20-30% exaggerated exaggerated ? 
Quantal content ~30-50 increased same or reduced reduced 




Comparison of the main neuromuscular electrophysiological features of mouse models of 
AChR, MuSK and LRP myasthenia gravis variants. CMAP = compound muscle action 




Figure 1. Schematic drawing of the neuromuscular junction and the localization of the key 





Figure 2. Electrophysiological signals at the myasthenic neuromuscular junction (NMJ). 
With intracellular micro-electrode measurements the spontaneous miniature endplate 
potentials (MEPPs) and nerve-stimulation evoked endplate potentials (EPPs) can be recorded 
from the muscle fibre near the NMJ. (A) Examples of severely reduced MEPP amplitude at a 
myasthenic NMJ from a passive transfer myasthenia gravis mouse model, indicating reduced 
ACh receptor density due to the autoantibody attack. In the top row pictures ten recorded 
sweeps of 1 s duration have been superimposed. Bottom row show exemplary MEPPs at 
magnified time scale.  (B) Schematic illustration of the reduced safety factor at the 
myasthenic NMJ (right), as compared to a normal control NMJ (left). The low safety factor is 
caused by the combination of EPPs being reduced due to loss of ACh receptors and an 
elevated firing threshold of the muscle fibre due to loss of postsynaptic NaV1.4 channels 
resulting from complement-mediated focal membrane damage. The physiological rundown of 
EPPs during high-rate activity brings the EPPs under the firing threshold at the myasthenic 
NMJ, and muscle fibre action potentials are no longer triggered. At the normal NMJ, EPPs 
remain supra-threshold in spite of their amplitude rundown, resulting in continuous 
successful synaptic transmission. (C) Recorded tetanic contraction of ex vivo mouse 
diaphragm muscles upon 40 Hz nerve stimulation. The muscle from the normal mouse (left) 
shows sustained contraction, while the muscle from a passive transfer myasthenia gravis 
mouse (right) shows fatigable weakness. Apparently, a proportion of the muscle fibres in this 
muscle has an NMJ with progressive block of neuromuscular transmission due to EPPs 
becoming subthreshold, such as depicted in (B).  
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